Masashi Takesada

Intellectual development in patients with untreated histidinemia. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan.

in the spread of malignant disease, Int J Cancer 11:704, 1973. 4. Weiss L: A pathobiologic overview of metastasis, Semin Oncol 4:5, 1977. 5. Fidler I J, Gerston DM, and Hart IR: The biology of cancer invasion and metastasis, Adv Cancer Res 28:149, 1978. 6. Gastpar H, and Weissgerber PW: The inhibition of cancer ceiI stickiness. A model for investigation of platelet aggregation inhibitors in vivo. V. The effect of penbutolol, J Med 12:1, 1981. 7. Agostino D, and Cliffton EE: Anticoagulants and the development of pulmonary metastases, Arch Surg 84:449, 1962. 8. Fisher B, and Fisher ER: Anticoagulants and tumor cell lodgment, Cancer Res 27:421, 1967. 9. Honn KV, Cicone B, and Skoff A: Prostacyclin: A potent antimetastatic agent, Science 212:1270, 1981. 10. Zeidman 1, and Buss JM: Transpulmonary passage of tumor cell emboli, Cancer Res 12:733, 1952. 11. Liotta LA, Kleinerman J, and Saidel GM: The significance of hematogenous tumor cell clumps in the metastatic process, Cancer Res 36:889, 1976. 12. Akyon MG, and Arslan G: Pulmonary embolism during surgery for a Witms tumour (nephroblastoma), Br J Anaesth 53:903, 1981. 13. Leape LL, Breslow NE, and Bishop HC: The surgical treatment of Wilms tumor: Results of the National Wilms Tumor Study, Ann Surg 187:351, 1978. 14. Gross RE: Embryoma of the kidney (Wilms tumor), in The surgery of infancy and childhood. Its principles and techniques, Philadelphia, 1953, WB Saunders Company, p 590.

Influence of pimozide on hypothalamo-pituitary function in children with behavioral disorders

Hypothalamo-pituitary functions were examined in thirteen children with behavioral disorders (six with hyperkinesia, four with autism, two with tic and one with schizophrenia) before and during treatment with pimozide, an antidopaminergic drug. The mean (+/- S.E.M.) basal serum PRL level (24.5 +/- 4.2 ng/ml) during pimozide treatment was significantly higher than that (12.4 +/- 3.2 ng/ml) before treatment. Hyperresponse of PRL to TSH releasing hormone (TRH) was observed in five (three with hyperkinesia, one with tic and one with autism) of the thirteen patients before treatment and in seven (four with hyperkinesia, two with autism and one with tic) during treatment. Mean TSH response during treatment was not significantly different from that before treatment. However, three of the four autistic children showed hyperresponse of TSH to TRH before treatment, whereas only one also showed a hyperresponse during treatment. The pimozide treatment had no demonstrable influence on GH or cortisol secretion in response to insulin-induced hypoglycemia, or on serum T4 and T3 levels.